Martin Schrappe
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
Year:
2026
Year:
2026
Year:
2026
Year:
2025
PURPOSE Modern ALL therapy aims to reduce toxicity, while maintaining and improving the current high cure rates. Acute and late sequelae of anthracyclines are of major concern. The AIEOP-BFM ALL 2009 trial aimed to clarify the need for anthracyclines in low-risk patients. PATIENTS AND METHODS After 2 weeks of induction therapy, which included two daunorubicin (DNR) doses once weekly (30 mg/m 2 each) as part of a 4-drug therapy, patients age 1-17 years with newly diagnosed non–high-risk B-ALL either positive for ETV6::RUNX1 or with rapid treatment response, as assessed by induction day-15 evaluation, were randomly assigned to receive either two additional doses of DNR (control arm [CA]) or no further DNR during induction (experimental arm [EA]). Patients treated as randomly assigned were included in the primary analysis on noninferiority in event-free survival (EFS). Adverse reactions of special interest (ARSI) were analyzed in the as-treated population. RESULTS Of 6,136 patients enrolled in AIEOP-BFM ALL 2009, 2,514 patients (41.0%) were eligible for this random assignment, with 82.7% actually randomly assigned (EA: n = 1,040 and CA: n = 1,039). The 5-year EFS was 92.5% (SE 0.8%) in CA and 92.2% (SE 0.9%) in EA. Accordingly, cumulative incidence of relapse was 5.8% (SE 0.7%) and 5.7% (SE 0.7%), and overall survival was 97.6% (SE 0.5%) and 97.4% (SE 0.5%) in CA and EA, respectively. Life-threatening and fatal ARSI were similar in the two arms, but there was a three times lower incidence of invasive fungal infections in the EA (0.5% v 1.5%, P = .02). CONCLUSION A reduced DNR dose during induction did not compromise the outcome of patients with favorable prognostic factors but did diminish infectious toxicity indicated by the lower rate of invasive fungal infections.
Year:
2025
A–C, Multivariate Cox proportional hazard model for EFS. The variables “vitamin D deficiency” (defined by a 25 OH vitamin D level 47 pg/mL), sex and age at diagnosis were investigated for EFS in the groups: embryonal malignancies ( A ) lymphatic malignancies ( B ) and malignant primary brain tumor (PBT; C ).
Year:
2024
A and B, EFS in the entire group and in six diagnostic groups. HR and 95% confidence interval (CI) for the presence of a vitamin D deficiency (25 OH vitamin D level at or below 30 nmol/L) at any time during the 5 years following the initial diagnosis is shown in A , and for the presence of PTH levels at or above 47 pg/mL (= median of the group) is shown in B . A univariate analysis was performed.
Year:
2024
A–C, EFS in subgroups with PTH as a continuous variable. Visualizing of the highest measured PTH on time-to-event (as EFS) in a model assuming a linear PTH-effect in the subgroups of embryonal malignancies ( A ) lymphatic malignancies ( B ) and malignant primary brain tumor (PBT; C ). For the analyses, the highest PTH at diagnosis or during the following 5-year period was used.
Year:
2024
Clinical characteristics of the group of patients with PTH levels below the group-median (47 pg/mL; PTH− group, first column), the patients with PTH levels ≥ the median (PTH+ group, middle column), and the entire group (last column).
Year:
2024
A–C, Kaplan–Meier plots showing EFS in subgroups. The Kaplan–Meier plots show the EFS in the groups of embryonal malignancies ( A ) lymphatic malignancies ( B ) and malignant primary brain tumor (PBT; C ) for patients with PTH at/above the median (47 pg/mL) of the entire group (orange line) and patients with PTH levels below the median (gray line). For the analyses, the highest PTH at diagnosis or during the following 5-year period was used. P values from paired log rank tests are provided.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (35)
Shondra Pruett-Miller
Associate Member
St. Jude Children's Research Hospital
Mariko Eguchi
Profesor
Ehime University Graduate School of Medicine
Chi Kong Li
Professor
The Chinese University of Hong Kong (CUHK)
riccardo masetti
Assistant Professor
University of Bologna
Kjeld Schmiegelow
-
Hanne Vibeke Hansen Marquart
Chief Physician; MD, PhD, Clinical Associate Professor
Copenhagen University Hospital
Allen Eng Juh Yeoh
National University of Singapore (NUS)
Corinna Grasemann
Head of Pediatrics
University Medical Center of the Johannes Gutenberg University Mainz
Atsushi Manabe
Professor
Hokkaido University
Wolfgang Hoegler
Professor of Paediatrics
-
Gabriele Escherich
-
Valentino Conter
-
John Choi
The University of Alabama
Franco Locatelli
Full Professor of Pediatrics
Catholic University of the Sacred Heart
Steven Kornblau
Professor
The University of Texas MD Anderson Cancer Center
Junko Takita
教授 / Professor
Kyoto University
Szymon Skoczen
Associated Professor
Uniwersytet Jagiellonski Collegium Medicum
Kathryn Roberts
St. Jude Children's Research Hospital
David Teachey
Professor
Children's Hospital of Philadelphia
Cristina Matteo
Istituto di Ricerche Farmacologiche Mario Negri IRCCS
Daisuke Tomizawa
Head
National Center For Child Health and Development
Cheng Cheng
Professor
St Jude Grade School of Biomedical Sciences
Motohiro Kato
-
Takao Deguchi
Head of Division
National Center For Child Health and Development
Ching-Hon Pui
Fahad Nasser Al-Rashid Chair of Leukemia Research
St. Jude Children's Research Hospital
Andrew Moore
Associate Professor
University of Queensland
Ilaria Iacobucci
Principal Scientist
St. Jude Children's Research Hospital
Masatoshi Takagi
Tokyo Medical and Dental University
Zhaohui Gu
Assistant Professor
Beckman Research Institute, City of Hope
Paul G Thomas
Professor
Fred Hutch Cancer Center
Andishe Attarbaschi
Medical University of Vienna
Carmelo Rizzari
Professor
University of Milano-Bicocca
Charles Mullighan
Senior Deputy Director, St. Jude Children's Research Hospital Comprehensive Cancer Center
St. Jude Children's Research Hospital
Rishi Kotecha
Professor
Telethon Kids Institute
Klaus-Michael Debatin
Professor of Pediatrics
Universität Ulm
Make your next move.
Prepare your application
Review drafts before you send them.